RNA测序分析揭示ITGAL/CD11A作为小鼠低级别胶质瘤生长的基质调控因子
本研究利用RNA测序荟萃分析、基因工程小鼠和人类标本,发现胶质瘤相关微胶质细胞中Itgal/CD11a富集,且在人低级别胶质瘤标本中同样升高。CD11a缺失影响微胶质细胞Cx3cr1表达和迁移及胶质瘤促有丝分裂因子Ccl5产生,抗体抑制CD11a可减少小鼠Nf1低级别胶质瘤生长。
要点
- ITGAL/CD11A在胶质瘤相关微胶质细胞中富集,并在人低级别胶质瘤中升高。
- CD11a对微胶质细胞Cx3cr1表达、CX3CL1定向迁移及Ccl5产生至关重要。
- 抗体介导的CD11a抑制可减少小鼠Nf1低级别胶质瘤在体生长。
核心结论
- ITGAL/CD11A是低级别胶质瘤生物学中的关键微胶质细胞调控因子,可能成为基质靶向治疗策略的靶点。
研究设计与样本
- 研究采用RNA测序荟萃分析、基因工程小鼠模型和人类生物标本,包括CD11a缺陷小鼠的体外功能研究及抗CD11a中和抗体治疗Nf1视神经胶质瘤小鼠的在体评估。
主要发现
- 在胶质瘤相关微胶质细胞中鉴定出Itgal/CD11a富集,并在多个独立生成的Nf1视神经胶质瘤小鼠模型中得到证实。
- 人低级别胶质瘤(毛细胞型星形细胞瘤)标本中ITGAL/CD11A表达同样升高,特异性地存在于这些肿瘤的微胶质细胞中。
- CD11a表达对小鼠微胶质细胞CX3CL1受体(Cx3cr1)表达、CX3CL1定向迁移及胶质瘤促有丝分裂因子(Ccl5)产生至关重要。
- 抗体介导的CD11a抑制减少了小鼠Nf1低级别胶质瘤的在体生长。
临床怎么用
- 研究提示靶向ITGAL/CD11A的微胶质细胞调控可能成为低级别胶质瘤的基质靶向治疗策略,但尚未进入临床实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Emerging insights from numerous laboratories have revealed important roles for nonneoplastic cells in the development and progression of brain tumors. One of these nonneoplastic cellular constituents, glioma-associated microglia (GAM), represents a unique population of brain monocytes within the tumor microenvironment that have been reported to both promote and inhibit glioma proliferation. To elucidate the role of GAM in the setting of low-grade glioma (LGG), we leveraged RNA sequencing meta-analysis, genetically engineered mouse strains, and human biospecimens. METHODS: Publicly available disease-associated microglia (DAM) RNA-seq datasets were used, followed by immunohistochemistry and RNAScope validation. CD11a-deficient mouse microglia were used for in vitro functional studies, while LGG growth in mice was assessed using anti-CD11a neutralizing antibody treatment of Neurofibromatosis type 1 (Nf1) optic glioma mice in vivo. RESULTS: We identified Itgal/CD11a enrichment in GAM relative to other DAM populations, which was confirmed in several independently generated murine models of Nf1 optic glioma. Moreover, ITGAL/CD11A expression was similarly increased in human LGG (pilocytic astrocytoma) specimens from several different datasets, specifically in microglia from these tumors. Using CD11a-knockout mice, CD11a expression was shown to be critical for murine microglia CX3CL1 receptor (Cx3cr1) expression and CX3CL1-directed motility, as well as glioma mitogen (Ccl5) production. Consistent with an instructive role for CD11a+ microglia in stromal control of LGG growth, antibody-mediated CD11a inhibition reduced mouse Nf1 LGG growth in vivo. CONCLUSIONS: Collectively, these findings establish ITGAL/CD11A as a critical microglia regulator of LGG biology relevant to future stroma-targeted brain tumor treatment strategies.
引用
- De Andrade Costa A, Chatterjee J, Cobb O, et al. RNA sequence analysis reveals ITGAL/CD11A as a stromal regulator of murine low-grade glioma growth. Neuro Oncol. 2022. PMID: 34043012. doi:10.1093/neuonc/noab130
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。